▲ A study has shown that second-line non-insulin antidiabetic drugs, such as GLP-1 receptor agonists, do not increase the risk of congenital malformations during pregnancy. (Photo = DB)
[메디컬투데이=최재백 기자] Second-line, non-insulinogenic antidiabetic agents, such as glucagon-like peptide (GLP-1) receptor agonists, do not increase the risk of congenital malformations during pregnancy, a study suggests.
A study published in the journal JAMA Internal Medicine found that second-line non-insulin antidiabetic treatments, such as GLP-1 receptor agonists, do not increase the risk of congenital malformations during pregnancy compared to insulin treatment.
Pregestational diabetes is a risk factor for various complications that may occur during pregnancy, but the safety of using second-line non-insulin antidiabetic agents during pregnancy has not been sufficiently proven, so their use in pregnant women has been limited.
Recently, a research team at the Harvard TH Chan School of Public Health in Boston analyzed more than 3.5 million pregnancy cases from Finland, Iceland, Norway, Sweden, Israel, and the United States between 2009 and 2021, and 2. The safety of tea non-insulin antidiabetic agents was evaluated.
About 52,000 people had type 2 diabetes before pregnancy, and about 15,000 people were prescribed and taking first- or second-line non-insulin antidiabetic drugs three months before or three months after pregnancy.
The research team found that children of mothers with type 2 diabetes before pregnancy had a significantly higher frequency of major congenital malformations, including heart defects, than the general newborn population, but children of mothers with type 2 diabetes who took second-line non-insulin antidiabetic drugs had a significantly higher incidence of insulin deficiency. It was reported that the risk of major congenital malformations was not increased compared to children of mothers who received treatment.
They showed an increasing trend in the use of second-line non-insulin antidiabetic agents, especially GLP-1 receptor agonists, during the study period and predicted that the number of newborns exposed to these drugs would continue to increase in the future.
They concluded that newly developed non-insulin antidiabetic drugs do not increase the risk of major congenital malformations when used early in pregnancy.
In particular, they are very similar to Metformin or Glyburide, which were used in the past to treat diabetes before pregnancy, as second-line non-insulinic antidiabetic agents such as GLP-1 receptor agonists are very similar to the treatment of type 2 diabetes patients in early pregnancy. It was expected that it could be safely used to control blood sugar levels.
[ⓒ 메디컬투데이. 무단전재-재배포 금지]
2023-12-24 03:12:08
#GLP1 #receptor #agonists #control #diabetes #safe #pregnancy
